2. UroToday Home
  3. Transformative Evidence
  4. Treatment Considerations in the First Line Setting of mCRPC

RALU Study Videos

Optimal Treatment Sequencing with Radiopharmaceuticals After Radium-223 in Men with Newly Progressed Prostate Cancer – A Cased Based Review - Phillip Koo, Neal Shore, & Alicia Morgans

Optimal Treatment Sequencing with Radiopharmaceuticals After Radium-223 in Men with Newly Progressed Prostate Cancer – A Cased Based Review - Phillip Koo, Neal Shore, & Alicia Morgans

Details
In this conversation, Alicia Morgans, Phillip Koo, and Neal Shore evaluate a patient case of a 63-year-old man who was diagnosed with de novo metastatic prostate cancer in January 2020. He was initially treated for metastatic hormone-sensitive prostate cancer with enzalutamide plus ADT. He presents again now with progression of bone-only metastatic disease. Drs Shore, Koo, and Morgans talk through...
Sequencing of Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer - Pedro Barata

Sequencing of Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer - Pedro Barata

Details
In this conversation, Pedro Barata and Alicia Morgans talk discuss the sequencing of radiopharmaceuticals in metastatic castration-resistant prostate cancer. Reviewing several trials in this treatment landscape, including data from ALSYMPCA, VISION, REASSURE, WARMTH, and more recently, the RALU study Pedro Barata presents several different treatment scenarios where we can fit radium-223, among all...
223Ra Use Before 177Lu-PSMA for Patients with Bone-predominant mCRPC, The RAdium LUtetium (RALU) Study, Journal Club - Christopher Wallis & Zachary Klaassen

223Ra Use Before 177Lu-PSMA for Patients with Bone-predominant mCRPC, The RAdium LUtetium (RALU) Study, Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club Chris Wallis and Zach Klaassen highlight a Journal of Nuclear Medicine publication entitled Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study . The RAdium LUtetium (RALU) study evaluated the feasibility of sequential al...
email news signup